Carlyn Tan

40PUBLICATIONS
181CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene expression (incl. microarray and other genome-wide approaches)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Nov 04, 2026
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma.

|Jul 29, 2026
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

|Jun 17, 2026
Practical Management of Bispecific Antibodies in Multiple Myeloma.

|Jun 12, 2026
Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.

|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

Pageof 7

Frequent Collaborators

28 joint publications

Neha Korde

28 joint publications

Urvi Shah

26 joint publications

Malin L Hultcrantz

25 joint publications

Heather Landau